drugset / Trial / NCT00998192
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
Timeline
- Start
- 2009-10
- Primary completion
- 2013-09
- Completion
- 2015-08
Outcome
Met primary endpoint
release “met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung” oncolyticsbiotech.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REOLYSIN® | Other / unclassified | 3e+10 unknown | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |